title: Long-term treatment of systemic juvenile idiopathic arthritis with tocilizumab: results of an open-label extension study in Japan.
authors.forename: Shumpei
authors.initials: S
authors.lastname: Yokota
authors.forename: Tomoyuki
authors.initials: T
authors.lastname: Imagawa
authors.forename: Masaaki
authors.initials: M
authors.lastname: Mori
authors.forename: Takako
authors.initials: T
authors.lastname: Miyamae
authors.forename: Syuji
authors.initials: S
authors.lastname: Takei
authors.forename: Naomi
authors.initials: N
authors.lastname: Iwata
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Umebayashi
authors.forename: Takuji
authors.initials: T
authors.lastname: Murata
authors.forename: Mari
authors.initials: M
authors.lastname: Miyoshi
authors.forename: Minako
authors.initials: M
authors.lastname: Tomiita
authors.forename: Norihiro
authors.initials: N
authors.lastname: Nishimoto
authors.forename: Tadamitsu
authors.initials: T
authors.lastname: Kishimoto
mesh_terms: D000293:Adolescent; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage* / Q000009:adverse effects; D018501:Antirheumatic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D001171:Arthritis, Juvenile / Q000188:drug therapy*; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007564:Japan; D008297:Male; D016896:Treatment Outcome
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; C502936:tocilizumab